Glibenclamide

Diabeta, Glyburide, Glynase, Micronase (glyburide) is a small molecule pharmaceutical. Glyburide was first approved as Diabeta on 1984-05-01. It is used to treat type 2 diabetes mellitus in the USA. The pharmaceutical is active against ATP-sensitive inward rectifier potassium channel 11. In addition, it is known to target cystic fibrosis transmembrane conductance regulator, ATP-sensitive inward rectifier potassium channel 8, solute carrier organic anion transporter family member 2B1, and aldo-keto reductase family 1 member C1.